miRNA and Cancer - 1st Edition - ISBN: 9780128119228, 9780128119235

miRNA and Cancer, Volume 135

1st Edition

Series Editors: Kenneth D. Tew
Serial Volume Editors: Paul B. Fisher Carlo Croce
eBook ISBN: 9780128119235
Hardcover ISBN: 9780128119228
Imprint: Academic Press
Published Date: 2nd September 2017
Page Count: 230
Sales tax will be calculated at check-out Price includes VAT/GST
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
30% off
122.00
85.40
85.40
85.40
85.40
104.00
72.80
72.80
72.80
72.80
171.00
119.70
119.70
119.70
119.70
Unavailable
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. MicroRNAs and Cancer: A Long Story for Short RNAs

Alessandra Drusco and Carlo M. Croce

2. The Enigma of miRNA Regulation in Cancer

Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher

3. Animal Models to Study microRNA Functions

Arpita S. Pal and Andrea L. Kasinski

4. Cancer Hallmarks and MicroRNAs: The Therapeutic Connection

Katrien Van Roosbroeck and George A. Calin

5. microRNAs in Cancer Susceptibility

Brid M. Ryan

6. Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy

Veronica Balatti, Yuri Pekarsky and Carlo M. Croce

7. MicroRNAs and Epigenetics

Catia Moutinho and Manel Esteller


Description

miRNA and Cancer, Volume 135, the latest volume in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents original reviews on research bridging oncology and gene expression, and includes specific chapters on Non-coding RNAs as Biomarkers of Cancer, The Enigma of microRNA Regulation in Cancer, Animal Models to Study microRNA functions, Non-coding RNAs and Cancer, microRNAs in Cancer Susceptibility, ts-RNAs versus microRNAs, microRNAs and AML, and microRNAs and Epigenetics.

Key Features

  • Provides information on cancer research
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology


Details

No. of pages:
230
Language:
English
Copyright:
© Academic Press 2017
Published:
Imprint:
Academic Press
eBook ISBN:
9780128119235
Hardcover ISBN:
9780128119228

Ratings and Reviews


About the Series Editors

Kenneth D. Tew Series Editor

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

About the Serial Volume Editors

Paul B. Fisher Serial Volume Editor

Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA

Carlo Croce Serial Volume Editor

Professor Carlo Croce is a renowned figure in the field of genetics and cancer. He has received numerous awards and accolades for his work, not least his research into the molecular mechanisms of leukemia which earned him the 2006 Clowes Memorial Award from the American Association for Cancer Research.

Affiliations and Expertise

Professor and Chair, Department of Cancer Biology and Genetics, College of Medicine, Ohio State University